Shares of Arcutis Biotherapeutics Inc. (ARQT) have nearly doubled in value over the past year, thanks to the success of its flagship product ZORYVE, which has been developed as a portfolio of innovative topical therapies that is redefining the treatment of chronic inflammatory skin diseases and demonstrating strong, sustainable commercial momentum across all strengths and indications.
ZORYVE is a next-generation small molecule inhibitor of phosphodiesterase-4 (PDE4) that has been implicated in a wide range of inflammatory diseases. It is available in cream and foam formulations at multiple strengths, has been approved for several indications, and is being explored for further uses.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com